Overview

BAY43-9006 - Phase II Study in Non-Small Cell Lung Carcinoma (NSCLC)

Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate if BAY43-9006 has an effect on the tumors, how long the effect continues, if the patients receiving BAY43-9006 will live longer. - If BAY43-9006 has an effect on the quality of life of patients with non-small cell lung cancer. - If BAY43-9006 helps to slow the worsening of non-small cell lung cancer. - If BAY43-9006 prevents the growth of, or shrinks non-small cell lung tumors and/or their metastases.
Phase:
Phase 2
Details
Lead Sponsor:
Bayer
Collaborators:
Amgen
Onyx Pharmaceuticals
Treatments:
Niacinamide
Sorafenib